Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GMAB
stocks logo

GMAB

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.02B
+13.62%
0.434
-48.04%
921.55M
+29.43%
0.000
-100%
1.05B
+13.48%
0.000
-100%
Estimates Revision
The market is revising Upward the revenue expectations for Genmab A/S (GMAB) for FY2025, with the revenue forecasts being adjusted by 0.4% over the past three months. During the same period, the stock price has changed by 16.27%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.4%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+6.69%
In Past 3 Month
Stock Price
Go Up
up Image
+16.27%
In Past 3 Month
Wall Street analysts forecast GMAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMAB is 41.00 USD with a low forecast of 32.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast GMAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMAB is 41.00 USD with a low forecast of 32.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
1 Hold
1 Sell
Moderate Buy
Current: 32.020
sliders
Low
32.00
Averages
41.00
High
48.00
Current: 32.020
sliders
Low
32.00
Averages
41.00
High
48.00
H.C. Wainwright
Buy
maintain
$40 -> $41
2025-11-10
Reason
H.C. Wainwright
Price Target
$40 -> $41
2025-11-10
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Genmab to $41 from $40 and keeps a Buy rating on the shares following the Q3 report. Darzalex Faspro is now FDA approved in high-risk smoldering multiple myeloma, the analyst tells investors in a research note.
Citi
Buy -> Neutral
downgrade
$101 -> $97
2025-09-29
Reason
Citi
Price Target
$101 -> $97
2025-09-29
downgrade
Buy -> Neutral
Reason
Citi downgraded Merus (MRUS) to Neutral from Buy with a price target of $97, down from $101, after the company entered into an agreement pursuant to which Genmab (GMAB) will acquire all the shares of Merus for $97.00 per share in an all-cash transaction, representing a transaction value of $8.0B. The firm views the possibility of a competing bid as very low.
Guggenheim
Michael Schmidt
Neutral -> Buy
upgrade
$43
2025-09-23
Reason
Guggenheim
Michael Schmidt
Price Target
$43
2025-09-23
upgrade
Neutral -> Buy
Reason
Guggenheim analyst Michael Schmidt upgraded Genmab to Buy from Neutral with a $43 price target.
JPMorgan
Neutral
maintain
2025-09-11
Reason
JPMorgan
Price Target
2025-09-11
maintain
Neutral
Reason
JPMorgan raised the firm's price target on Genmab to DKK 1,650 from DKK 1,500 and keeps a Neutral rating on the shares.
Deutsche Bank
NULL -> Buy
maintain
2025-08-28
Reason
Deutsche Bank
Price Target
2025-08-28
maintain
NULL -> Buy
Reason
Deutsche Bank raised the firm's price target on Genmab to DKK 1,900 from DKK 1,750 and keeps a Buy rating on the shares.
H.C. Wainwright
Buy
maintain
$35 -> $36
2025-08-15
Reason
H.C. Wainwright
Price Target
$35 -> $36
2025-08-15
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Genmab to $36 from $35 and keeps a Buy rating on the shares following the Q2 report. The firm sees potential FDA approval by November 30 for the combination of epcoritamab plus rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Genmab A/S (GMAB.O) is 22.37, compared to its 5-year average forward P/E of 39.31. For a more detailed relative valuation and DCF analysis to assess Genmab A/S 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
39.31
Current PE
22.37
Overvalued PE
66.72
Undervalued PE
11.91

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
28.40
Current EV/EBITDA
8.31
Overvalued EV/EBITDA
54.81
Undervalued EV/EBITDA
1.99

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
10.26
Current PS
4.67
Overvalued PS
15.99
Undervalued PS
4.52
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

GMAB News & Events

Events Timeline

(ET)
2025-11-18
11:32:30
Genmab Receives FDA Approval for Epkinly Combination Therapy for Lymphoma
select
2025-11-18
10:20:54
FDA Grants Approval for Genmab's Epkinly to Treat Follicular Lymphoma
select
link
2025-11-06 (ET)
2025-11-06
11:08:15
Genmab confirms 2025 revenue forecast of $3.5B-$3.7B, in line with consensus of $3.7B
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
12-04Globenewswire
PinnedGenmab Closes $1.5 Billion Bond Offering to Acquire Merus
  • Successful Bond Offering: Genmab and its wholly owned subsidiary Genmab Finance have successfully closed a $1.5 billion offering of 6.250% senior secured notes, which is expected to fund the acquisition of Merus, thereby enhancing the company's market position in the biopharmaceutical sector.
  • Optimized Financing Structure: This bond issuance, combined with a new $2.0 billion senior secured term loan, ensures Genmab has sufficient funds for the acquisition of Merus and related expenses, thereby improving its financial flexibility and capital structure.
  • Acquisition Strategy Advancement: Genmab plans to utilize the proceeds from this financing to complete the acquisition of Merus, which is expected to further expand its product portfolio and enhance its R&D capabilities, driving future growth potential.
  • Risk Management Measures: The bond indentures include restrictive covenants that prevent Genmab and its subsidiaries from incurring excessive debt during the acquisition process, thereby reducing financial risk and maintaining investor confidence.
[object Object]
Preview
5.0
11-20Newsfilter
Share and Linked Security Transactions in Genmab A/S by Management and Their Close Associates

  • Company Announcement: Genmab A/S disclosed transactions made by managerial employees and their closely associated persons, in compliance with market regulations.

  • Power of Attorney: Managerial employees have authorized Genmab to publish their trading activities in the company's shares.

  • About Genmab: Established in 1999 and headquartered in Copenhagen, Genmab focuses on developing innovative antibody therapeutics to improve patient lives, with a vision to transform cancer treatment by 2030.

  • Forward-Looking Statements: The announcement includes forward-looking statements, highlighting potential risks and uncertainties that could affect future performance, with a reminder to refer to financial reports for detailed risk factors.

[object Object]
Preview
9.0
11-19NASDAQ.COM
FDA Approves EPKINLY Combination Therapy from AbbVie and Genmab for Relapsed or Refractory Follicular Lymphoma

  • FDA Approval: AbbVie Inc. announced that the FDA has approved EPKINLY in combination with rituximab and lenalidomide for treating adult patients with relapsed or refractory follicular lymphoma, providing a chemotherapy-free option.

  • Clinical Trial Results: The approval was based on the phase 3 EPCORE FL-1 trial, which showed a 79% reduction in the risk of disease progression or death and an overall response rate of 89% for the EPKINLY + R2 combination.

  • Safety and Administration: The regimen was found to be generally manageable in terms of safety and is suitable for outpatient administration, emphasizing its convenience for patients.

  • Collaboration and Future Presentation: AbbVie is collaborating with Genmab A/S on EPKINLY's development, and data from the EPCORE FL-1 study will be presented at the American Society of Hematology meeting in December 2025.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Genmab A/S (GMAB) stock price today?

The current price of GMAB is 32.02 USD — it has increased 1.07 % in the last trading day.

arrow icon

What is Genmab A/S (GMAB)'s business?

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

arrow icon

What is the price predicton of GMAB Stock?

Wall Street analysts forecast GMAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMAB is 41.00 USD with a low forecast of 32.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Genmab A/S (GMAB)'s revenue for the last quarter?

Genmab A/S revenue for the last quarter amounts to 1.02B USD, increased 25.25 % YoY.

arrow icon

What is Genmab A/S (GMAB)'s earnings per share (EPS) for the last quarter?

Genmab A/S. EPS for the last quarter amounts to 6.46 USD, increased 121.23 % YoY.

arrow icon

What changes have occurred in the market's expectations for Genmab A/S (GMAB)'s fundamentals?

The market is revising Upward the revenue expectations for Genmab A/S (GMAB) for FY2025, with the revenue forecasts being adjusted by 0.4% over the past three months. During the same period, the stock price has changed by 16.27%.
arrow icon

How many employees does Genmab A/S (GMAB). have?

Genmab A/S (GMAB) has 2682 emplpoyees as of December 05 2025.

arrow icon

What is Genmab A/S (GMAB) market cap?

Today GMAB has the market capitalization of 19.73B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free